Literature DB >> 1155341

Hemodynamic effect of dobutamine in patients with severe heart failure.

N Akhtar, E Mikulic, J N Cohn, M H Chaudhry.   

Abstract

Dobutamine, a derivative of dopamine, was infused at a rate of 10 mug/kg per min in 15 patients with severe congestive heart failure. Cardiac output increased from an average of 3.1 to 5.6 liters/min (P less than 0.001) with no change in mean arterial pressure (93.3 to 98.2 mm Hg) and only a slight increase in heart rate (98.5 to 105.2 beats/min) (P less than 0.02). Pulmonary wedge pressure was decreased from an average of 27.4 to 21.1 mm Hg (P less than 0.001). In seven patients a dose of 5 mug/kg per min also produced a significant increase in cardiac output but the effect was less than with the 10 mug/kg per min dose. No side effects were observed during the infusion. Dobutamine therefore is a potent inotropic drug with limited chronotropic and peripheral vascular effects and deserves therapeutic trial in the short-term management of low output heart failure.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1155341     DOI: 10.1016/0002-9149(75)90526-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  28 in total

1.  Comparative haemodynamic effects of dobutamine and isoproterenol in man.

Authors:  M Rigaud; J Boschat; P Rocha; A Ferreira; J Bardet; J P Bourdarias
Journal:  Intensive Care Med       Date:  1977-08       Impact factor: 17.440

2.  Bretylium and dobutamine in the treatment of coronary artery disease.

Authors:  W H Frishman
Journal:  Bull N Y Acad Med       Date:  1979-09

Review 3.  Treatment of end stage dilated cardiomyopathy.

Authors:  J B O'Connell; C K Moore; H C Waterer
Journal:  Br Heart J       Date:  1994-12

4.  Comparison of dobutamine and dopamine in treatment of severe heart failure.

Authors:  J D Stoner; J L Bolen; D C Harrison
Journal:  Br Heart J       Date:  1977-05

5.  Cardiovascular effects of prenalterol on rest and exercise haemodynamics in patients with chronic congestive cardiac failure.

Authors:  A C Tweddel; R G Murray; D Pearson; W Martin; I Hutton
Journal:  Br Heart J       Date:  1982-04

6.  Treatment of chronic heart failure with pirbuterol: acute haemodynamic responses.

Authors:  J R Dawson; R Canepa-Anson; P Kuan; N H Whitaker; J Carnie; C Warnes; S R Reuben; P A Poole-Wilson; G C Sutton
Journal:  Br Med J (Clin Res Ed)       Date:  1981-05-02

7.  The cardiovascular pharmacology of 7-propyl-theo-phylline-dopamine (D4975); comparison with dopamine and dobutamine.

Authors:  D McCaig; J R Parratt
Journal:  Br J Pharmacol       Date:  1979-10       Impact factor: 8.739

8.  Dobutamine in elderly septic shock patients refractory to dopamine.

Authors:  B Tell; T C Majerus; L Flancbaum
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

9.  A review of the haemodynamic effects of labetalol in man.

Authors:  J N Cohn; J Mehta; G S Francis
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

10.  Dobutamine in the treatment of depressed cardiac function: a study in patients with ischaemic heart disease during the early post-operative period.

Authors:  M Pinaud; P Desjars; F Nicolas
Journal:  Intensive Care Med       Date:  1978-04       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.